BR101801 not checked

Boryung Pharmaceutical Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Peripheral T Cell Lymphoma
Main trialPhase 2
“The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).”In the company’s words, NCT07180771 on ClinicalTrials.gov
Other names
Bosmolisib

Other drugs for Peripheral T Cell Lymphoma

All 34 drugs for Peripheral T Cell Lymphoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Sep 2027 A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
Phase 1Completed 21 Sep 2023 BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BR101801

Following is part of Solo: you see every change to BR101801 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in